Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 10;39(32):3647-3648.
doi: 10.1200/JCO.21.01716. Epub 2021 Sep 10.

Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?

Maho Tanaka  1 , Akihiko Shimomura  1 , Hiroyuki Terakado  1 , Chikako Shimizu  1
Affiliations
Comment

Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?

Maho Tanaka et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Akihiko ShimomuraHonoraria: Chugai Pharma, AstraZeneca, Pfizer, Novartis, Eisai, Lilly, Daiichi Sankyo/UCB Japan, Kyowa Kirin InternationalConsulting or Advisory Role: Lilly Japan, AstraZeneca, PfizerResearch Funding: Chugai Pharma, AstraZeneca, Daiichi Sankyo, Mochida Pharmaceutical Co Ltd, Taiho Pharmaceutical Chikako ShimizuHonoraria: AstraZeneca, Kyowa Hakko Kirin, Chugai Pharma, Taiho Pharmaceutical, PfizerConsulting or Advisory Role: AstraZeneca, MSDResearch Funding: LillyNo other potential conflicts of interest were reported.

Comment in

  • Reply to M. Tanaka et al.
    Tolaney SM, Partridge AH, Winer EP, Krop IE. Tolaney SM, et al. J Clin Oncol. 2021 Nov 10;39(32):3648-3649. doi: 10.1200/JCO.21.01967. Epub 2021 Sep 10. J Clin Oncol. 2021. PMID: 34506210 No abstract available.

Comment on

  • Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
    Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Tolaney SM, et al. J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2. J Clin Oncol. 2021. PMID: 34077270 Clinical Trial.